… analysis of the ENGAGE AF-TIMI 48 trial in patients with AF, … and the relative efficacy and
safety of edoxaban vs. warfarin. Our … death, the efficacy and safety profile of edoxaban would be …

… [1] [2] [3] [4] Limited data are available on the efficacy and safety of NOACs in patients at the
… in the ENGAGE AF–TIMI 48 trial the outcome of atrial fibrillation (AF) patients differed across …

… on the efficacy and safety of DOAC in older people with AF … of the ENGAGE AF-TIMI 48 trial
was that edoxaban was … with warfarin, with similar efficacy in stroke and systemic embolism …

… edoxaban in very elderly ELDERCARE-AF patients with those in ENGAGE AF-TIMI 48,
edoxaban 15 mg appears to be therapeutically effective for very elderly patients. This is based on …

… Female sex is an independent risk factor for stroke and systemic embolic events in patients
with atrial fibrillation. This study aimed to examine the efficacy and safety profile of edoxaban …

… in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) phase
3 trial, 8 both once-daily doses of edoxaban (a high dose of 60 mg [or 30 mg in patients who …

… score for edoxaban. The trial design and data collection in ENGAGE AF-TIMI 48 precluded
… Forty percent of the patients randomized to warfarin were naïve to VKA at study enrollment, …

… In this analysis of patient-level hospitalization rates from the ENGAGE AF–TIMI 48 trial,
edoxaban 60/30 mg significantly reduced the overall rate of cardiovascular- or bleeding-related …

… the ENGAGE AF-TIMI 48 trial. Studies investigating comparative effectiveness and safety for
edoxaban in … Real-life performance of edoxaban in elderly patients with atrial fibrillation: a …

… in the setting of edoxaban vs warfarin plus pharmacodynamic … patients with AF regarding
safety of anticoagulation. Using data from ENGAGE AF-TIMI 48, we investigated ICH patients’ …